Biogen Inc (NASDAQ: BIIB) has reported E.P.S. of $-0.47 for its third fiscal quarter (ending September 30) versus $7.86 for the same period a year ago — a decline of -106%. This performance was $-4.46 short of the consensus estimate of $3.99. E.P.S. were $10.12 for the latest four quarters through September 30 versus $19.63 for the same period a year ago — a decline of -48%.
Recent Price Action
Biogen Inc (NASDAQ: BIIB) stock closed at $231.69 on 11/8/23 after a very large decline of -5.7%. The stock has performed in line with the market over the last nine months and has declined -2.5% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, BIIB is expected to continue to be a major Value Builder.
Biogen has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Biogen has a neutral Appreciation Score of 41 and a slightly negative Power Rating of 39, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment